A late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Our engineered viruses are designed to induce immunogenic death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection.
Lead Underwriter
BMO Capital Markets Corp, Credit Suisse Securities (USA) LLC Jefferies LLC, UBS Investment Bank
